CN102143739B - 用于最优化传递hiv附着抑制剂的稳定的药用组合物 - Google Patents

用于最优化传递hiv附着抑制剂的稳定的药用组合物 Download PDF

Info

Publication number
CN102143739B
CN102143739B CN200980135118.2A CN200980135118A CN102143739B CN 102143739 B CN102143739 B CN 102143739B CN 200980135118 A CN200980135118 A CN 200980135118A CN 102143739 B CN102143739 B CN 102143739B
Authority
CN
China
Prior art keywords
weight
compositions
hpmc
compound
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980135118.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN102143739A (zh
Inventor
J·R·布朗
H·托勒
A·B·丹尼斯
P·蒂明斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ViiV Healthcare UK No 5 Ltd
ViiV Healthcare UK No 4 Ltd
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of CN102143739A publication Critical patent/CN102143739A/zh
Application granted granted Critical
Publication of CN102143739B publication Critical patent/CN102143739B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CN200980135118.2A 2008-09-04 2009-09-03 用于最优化传递hiv附着抑制剂的稳定的药用组合物 Expired - Fee Related CN102143739B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9413108P 2008-09-04 2008-09-04
US61/094131 2008-09-04
PCT/US2009/055820 WO2010028108A2 (en) 2008-09-04 2009-09-03 Stable pharmaceutical composition for optimized delivery of an hiv attachment inhibitor

Publications (2)

Publication Number Publication Date
CN102143739A CN102143739A (zh) 2011-08-03
CN102143739B true CN102143739B (zh) 2014-12-17

Family

ID=41726353

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980135118.2A Expired - Fee Related CN102143739B (zh) 2008-09-04 2009-09-03 用于最优化传递hiv附着抑制剂的稳定的药用组合物

Country Status (16)

Country Link
US (2) US20100056540A1 (enExample)
EP (1) EP2323633B1 (enExample)
JP (1) JP5638527B2 (enExample)
CN (1) CN102143739B (enExample)
AT (1) ATE550016T1 (enExample)
CA (1) CA2735008C (enExample)
CY (1) CY1112816T1 (enExample)
DK (1) DK2323633T3 (enExample)
ES (1) ES2383149T3 (enExample)
HR (1) HRP20120441T1 (enExample)
NL (1) NL301118I2 (enExample)
PL (1) PL2323633T3 (enExample)
PT (1) PT2323633E (enExample)
SI (1) SI2323633T1 (enExample)
SM (1) SMT201200029B (enExample)
WO (1) WO2010028108A2 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9248139B2 (en) * 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209246A1 (en) * 2004-03-15 2005-09-22 Yasutsugu Ueda Prodrugs of piperazine and substituted piperidine antiviral agents
WO2007070589A2 (en) * 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023265A (en) * 1990-06-01 1991-06-11 Schering Corporation Substituted 1-H-pyrrolopyridine-3-carboxamides
US5124327A (en) * 1991-09-06 1992-06-23 Merck & Co., Inc. HIV reverse transcriptase
JP2686215B2 (ja) * 1993-04-28 1997-12-08 信越化学工業株式会社 徐放性錠剤
US5424329A (en) * 1993-08-18 1995-06-13 Warner-Lambert Company Indole-2-carboxamides as inhibitors of cell adhesion
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
US20040063744A1 (en) * 2002-05-28 2004-04-01 Tao Wang Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
US20060167044A1 (en) * 2004-12-20 2006-07-27 Arnaiz Damian O Piperidine derivatives and their use as anti-inflammatory agents
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050209246A1 (en) * 2004-03-15 2005-09-22 Yasutsugu Ueda Prodrugs of piperazine and substituted piperidine antiviral agents
WO2007070589A2 (en) * 2005-12-14 2007-06-21 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1h-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1h-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Williams Robert O III等.Investigation of excipient type and level on drug release from controlled release tablets containing HPMC.《pharmaceutical development and technology》.2002,第7卷(第2期),181-193. *

Also Published As

Publication number Publication date
CA2735008A1 (en) 2010-03-11
WO2010028108A2 (en) 2010-03-11
SMT201200029B (it) 2012-09-07
ES2383149T3 (es) 2012-06-18
PT2323633E (pt) 2012-05-29
CY1112816T1 (el) 2016-02-10
CN102143739A (zh) 2011-08-03
DK2323633T3 (da) 2012-07-09
NL301118I1 (enExample) 2021-07-23
US20150158891A1 (en) 2015-06-11
ATE550016T1 (de) 2012-04-15
PL2323633T3 (pl) 2012-08-31
JP2012502042A (ja) 2012-01-26
US20100056540A1 (en) 2010-03-04
EP2323633A2 (en) 2011-05-25
JP5638527B2 (ja) 2014-12-10
SI2323633T1 (sl) 2012-07-31
CA2735008C (en) 2016-11-29
HRP20120441T1 (hr) 2012-06-30
WO2010028108A3 (en) 2010-09-02
NL301118I2 (nl) 2022-02-22
EP2323633B1 (en) 2012-03-21

Similar Documents

Publication Publication Date Title
EP1441713B2 (en) Modified release tamsulosin tablets
EP1411921B2 (en) Pharmaceutical compositions containing terbinafine and use thereof
US10772888B2 (en) Solid pharmaceutical compositions containing an integrase inhibitor
AU2002321249A1 (en) Pharmaceutical compositions containing terbinafin and use thereof
WO2011098483A1 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
CN101784263A (zh) 奈韦拉平的延长释放制剂
CN102307575A (zh) 含醋氯芬酸的控释口服药制剂及其制造方法
CN102143739B (zh) 用于最优化传递hiv附着抑制剂的稳定的药用组合物
TW202333731A (zh) 用於治療癌症之VCP/p97抑制劑
US20230414567A1 (en) Methods of treating conditions related to the s1p1 receptor
WO2022111742A1 (es) Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer
EP3087978A1 (en) Sustained-release pharmaceutical composition containing acebrophylline and hydrophillic sustained-release agent
US20050013858A1 (en) Oral pharmaceutical compositions containing terbinafine
WO2024231312A2 (en) Combination therapy
CN118845683A (zh) 一种包含dpp-4抑制剂和二甲双胍的复方双层片
HK1067299B (en) Pharmaceutical compositions containing terbinafine and use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20180622

Address after: The Middlesex County

Co-patentee after: VIIV health UK fifth Ltd

Patentee after: VIIV health UK fourth Ltd

Address before: new jersey

Patentee before: Squibb Bristol Myers Co.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20141217

Termination date: 20190903

CF01 Termination of patent right due to non-payment of annual fee